Skip to main content

Table 2 Assessment schedule

From: A double-blind randomised controlled investigation into the efficacy of Mirococept (APT070) for preventing ischaemia reperfusion injury in the kidney allograft (EMPIRIKAL): study protocol for a randomised controlled trial

  1. Key
  2. Where an ’x’ is contained within a field, this denotes that the associated data is essential and if missed will be classified as a protocol deviation
  3. Where a ’Δ’ is contained within a field, this denotes that the associated data is desirable, and whilst every effort should be made to record these data, missing data will not constitute a protocol deviation
  4. eGFR estimated glomerular filtration rate, Hb haemoglobin, WBC white blood cells, RBP retinol binding protein, NAG N-acetyl-β-d-glucosaminidase, NGAL neutrophil gelatinase-associated lipocalin, CNI calcineurin inhibitor, PTLD, post-transplant lymphoproliferative disorder